
FDA Approves Corcept’s Lifyorli™ Combo for Platinum-Resistant Ovarian Cancer
FDA Clears Corcept’s Lifyorli™ (relacorilant) in Combination with Nab-Paclitaxel for Platinum-Resistant Ovarian Cancer Treatment Corcept Therapeutics Incorporated has announced a major regulatory milestone with the approval of its novel therapy,…













